Utility of assessing CD3(+) cell chimerism within the first months after allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia.

Bendjelloul M, Usureau C, Etancelin P, Saidak Z, Lebon D, Garçon L, Marolleau JP, Desoutter J, Guillaume N

Open source

DOI
10.1111/tan.14557
Published
2022 Jul
Container
HLA
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/tan.14557,
  title = {Utility of assessing CD3(+) cell chimerism within the first months after allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia.},
  author = {Bendjelloul M and Usureau C and Etancelin P and Saidak Z and Lebon D and Garçon L and Marolleau JP and Desoutter J and Guillaume N},
  year = {2022},
  journal = {HLA},
  doi = {10.1111/tan.14557},
  url = {https://doi.org/10.1111/tan.14557}
}

RIS

TY  - JOUR
TI  - Utility of assessing CD3(+) cell chimerism within the first months after allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia.
AU  - Bendjelloul M
AU  - Usureau C
AU  - Etancelin P
AU  - Saidak Z
AU  - Lebon D
AU  - Garçon L
AU  - Marolleau JP
AU  - Desoutter J
AU  - Guillaume N
PY  - 2022
JO  - HLA
DO  - 10.1111/tan.14557
UR  - https://doi.org/10.1111/tan.14557
ER  - 

APA

M, B., C, U., P, E., Z, S., D, L., L, G., JP, M., J, D., & N, G. (2022). Utility of assessing CD3(+) cell chimerism within the first months after allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia.. HLA. https://doi.org/10.1111/tan.14557

Source records